Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States for the treatment of hepatic veno-occlusive disease , a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation therapy. The three presentations include an update from an ongoing treatment investigational new drug study in the U.S., as well as updates from a number needed to treat analysis from a historically controlled pivotal Phase 3 trial in patients undergoing HSCT therapy, and from an international defibrotide compassionate use program.

http://ift.tt/19eqsif